

## **DURECT Corporation Invites You to Join its First Quarter 2015 Earnings Conference Call**

CUPERTINO, Calif., April 22, 2015 /PRNewswire/ — In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2015 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, April 30, 2015 at 4:30 pm Eastern Time (1:30 pm Pacific Time).

A live audio webcast of the presentation will be available by accessing DURECT's homepage at <a href="http://www.www.durect.com">http://www.www.durect.com</a> and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

## **About DURECT Corporation**

DURECT is a specialty pharmaceuticals company with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain management, acute organ injury and metabolic diseases. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. Late stage development programs of this nature include REMOXY® and POSIDUR™. DURECT's Epigenomic Regulator Program includes the lead molecule DUR-928 in Phase 1. DUR-928 is an endogenous small molecule that is an epigenomic modulator of cellular activities involved in lipid homeostasis, metabolic disease, inflammation and cell survival. For more information, please visit www.www.durect.com.

NOTE: POSIDUR<sup>™</sup>, SABER<sup>®</sup>, ORADUR<sup>®</sup>, and TRANSDUR<sup>®</sup> are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR, ORADUR-Methylphenidate, Relday and DUR-928 are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

To view the original version on PR Newswire, visit: <a href="http://www.prnewswire.com/news-releases/durect-corporation-invites-you-to-join-its-first-quarter-2015-earnings-conference-call-300070475.html">http://www.prnewswire.com/news-releases/durect-corporation-invites-you-to-join-its-first-quarter-2015-earnings-conference-call-300070475.html</a>

**SOURCE DURECT Corporation** 

Matthew J. Hogan, Chief Financial Officer, 408-777-4936